Essex Bio-Technology Buys Back 273,000 Shares, Expands Treasury Stock to Over 1 Million

Bulletin Express06-30

Essex Bio-Technology Limited disclosed that it repurchased 273,000 ordinary shares on 30 June 2026 through on-market transactions on the Hong Kong Stock Exchange.

• Transaction details – Repurchase volume: 273,000 shares – Price range: HKD 2.62–2.69 per share – Volume-weighted average price: HKD 2.6566 per share – Total consideration: HKD 0.73 million

• Share capital impact – Issued shares (excluding treasury shares) decreased to 566.00 million from 566.27 million, a 0.048 % reduction. – Treasury share balance rose to 1.01 million shares, bringing total issued shares (including treasury) to 567.01 million. – No repurchased shares have been cancelled to date; all are held as treasury shares.

• Mandate utilisation – Shareholders authorised a buy-back mandate on 26 May 2026 for up to 56.70 million shares. – Cumulative repurchases since the mandate: 1.01 million shares, representing 0.18 % of the company’s issued share capital on the mandate date.

• Post-repurchase restrictions – In accordance with HKEX rules, the company is subject to a moratorium on new share issues or treasury share sales until 30 July 2026.

All procedures were executed under the Hong Kong Listing Rules, with board authorisation and regulatory compliance confirmed by Director Fang Haizhou.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1190954706?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190954706","market":"hk","top_or_hot":-1,"title":"Essex Bio-Technology Buys Back 273,000 Shares, Expands Treasury Stock to Over 1 Million","media":"Bulletin Express","content":"<p>Essex Bio-Technology Limited disclosed that it repurchased 273,000 ordinary shares on 30 June 2026 through on-market transactions on the Hong Kong Stock Exchange.</p>\n<p>• Transaction details  \n  – Repurchase volume: 273,000 shares  \n  – Price range: HKD 2.62–2.69 per share  \n  – Volume-weighted average price: HKD 2.6566 per share  \n  – Total consideration: HKD 0.73 million</p>\n<p>• Share capital impact  \n  – Issued shares (excluding treasury shares) decreased to 566.00 million from 566.27 million, a 0.048 % reduction.  \n  – Treasury share balance rose to 1.01 million shares, bringing total issued shares (including treasury) to 567.01 million.  \n  – No repurchased shares have been cancelled to date; all are held as treasury shares.</p>\n<p>• Mandate utilisation  \n  – Shareholders authorised a buy-back mandate on 26 May 2026 for up to 56.70 million shares.  \n  – Cumulative repurchases since the mandate: 1.01 million shares, representing 0.18 % of the company’s issued share capital on the mandate date.</p>\n<p>• Post-repurchase restrictions  \n  – In accordance with HKEX rules, the company is subject to a moratorium on new share issues or treasury share sales until 30 July 2026.</p>\n<p>All procedures were executed under the Hong Kong Listing Rules, with board authorisation and regulatory compliance confirmed by Director Fang Haizhou.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Essex Bio-Technology Buys Back 273,000 Shares, Expands Treasury Stock to Over 1 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEssex Bio-Technology Buys Back 273,000 Shares, Expands Treasury Stock to Over 1 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-30 17:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Essex Bio-Technology Limited disclosed that it repurchased 273,000 ordinary shares on 30 June 2026 through on-market transactions on the Hong Kong Stock Exchange.</p>\n<p>• Transaction details  \n  – Repurchase volume: 273,000 shares  \n  – Price range: HKD 2.62–2.69 per share  \n  – Volume-weighted average price: HKD 2.6566 per share  \n  – Total consideration: HKD 0.73 million</p>\n<p>• Share capital impact  \n  – Issued shares (excluding treasury shares) decreased to 566.00 million from 566.27 million, a 0.048 % reduction.  \n  – Treasury share balance rose to 1.01 million shares, bringing total issued shares (including treasury) to 567.01 million.  \n  – No repurchased shares have been cancelled to date; all are held as treasury shares.</p>\n<p>• Mandate utilisation  \n  – Shareholders authorised a buy-back mandate on 26 May 2026 for up to 56.70 million shares.  \n  – Cumulative repurchases since the mandate: 1.01 million shares, representing 0.18 % of the company’s issued share capital on the mandate date.</p>\n<p>• Post-repurchase restrictions  \n  – In accordance with HKEX rules, the company is subject to a moratorium on new share issues or treasury share sales until 30 July 2026.</p>\n<p>All procedures were executed under the Hong Kong Listing Rules, with board authorisation and regulatory compliance confirmed by Director Fang Haizhou.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"","article_id":"1190954706","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190954706","pubTimestamp":1782810366,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Essex Bio-Technology Limited disclosed that it repurchased 273,000 ordinary shares on 30 June 2026 through on-market transactions on the Hong Kong Stock Exchange. • Transaction details     –...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技"},"translate_title":"Essex Bio-Technology回购273,000股，将库存股票扩大至超过100万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"Essex Bio-Technology Limited disclosed that it repurchased 273,000 ordinary shares on 30 June 2026 through on-market transactions on the Hong Kong Stock Exchange.\n• Transaction details  \n  – Repurchase volume: 273,000 shares  \n  – Price range: HKD 2.62–2.69 per share  \n  – Volume-weighted average price: HKD 2.6566 per share  \n  – Total consideration: HKD 0.73 million\n• Share capital impact  \n  – Issued shares (excluding treasury shares) decreased to 566.00 million from 566.27 million, a 0.048 % reduction.  \n  – Treasury share balance rose to 1.01 million shares, bringing total issued shares (including treasury) to 567.01 million.  \n  – No repurchased shares have been cancelled to date; all are held as treasury shares.\n• Mandate utilisation  \n  – Shareholders authorised a buy-back mandate on 26 May 2026 for up to 56.70 million shares.  \n  – Cumulative repurchases since the mandate: 1.01 million shares, representing 0.18 % of the company’s issued share capital on the mandate date.\n• Post-repurchase restrictions  \n  – In accordance with HKEX rules, the company is subject to a moratorium on new share issues or treasury share sales until 30 July 2026.\nAll procedures were executed under the Hong Kong Listing Rules, with board authorisation and regulatory compliance confirmed by Director Fang Haizhou.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1190954706","isCrawlerRequest":true}